These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Badorff C; Lee GH; Lamphear BJ; Martone ME; Campbell KP; Rhoads RE; Knowlton KU Nat Med; 1999 Mar; 5(3):320-6. PubMed ID: 10086389 [TBL] [Abstract][Full Text] [Related]
3. Cleavage of osmosensitive transcriptional factor NFAT5 by Coxsackieviral protease 2A promotes viral replication. Qiu Y; Ye X; Zhang HM; Hanson P; Zhao G; Tong L; Xie R; Yang D PLoS Pathog; 2017 Dec; 13(12):e1006744. PubMed ID: 29220410 [TBL] [Abstract][Full Text] [Related]
4. CVB infection and mechanisms of viral cardiomyopathy. Knowlton KU Curr Top Microbiol Immunol; 2008; 323():315-35. PubMed ID: 18357777 [TBL] [Abstract][Full Text] [Related]
5. Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. Badorff C; Knowlton KU Med Microbiol Immunol; 2004 May; 193(2-3):121-6. PubMed ID: 12920582 [TBL] [Abstract][Full Text] [Related]
6. Dissociation of sarcoglycans and the dystrophin carboxyl terminus from the sarcolemma in enteroviral cardiomyopathy. Lee GH; Badorff C; Knowlton KU Circ Res; 2000 Sep; 87(6):489-95. PubMed ID: 10988241 [TBL] [Abstract][Full Text] [Related]
7. Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: A protective mechanism against enteroviral cardiomyopathy. Badorff C; Fichtlscherer B; Rhoads RE; Zeiher AM; Muelsch A; Dimmeler S; Knowlton KU Circulation; 2000 Oct; 102(18):2276-81. PubMed ID: 11056105 [TBL] [Abstract][Full Text] [Related]
8. Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. Badorff C; Berkely N; Mehrotra S; Talhouk JW; Rhoads RE; Knowlton KU J Biol Chem; 2000 Apr; 275(15):11191-7. PubMed ID: 10753926 [TBL] [Abstract][Full Text] [Related]
9. Enteroviral cardiomyopathy: bad news for the dystrophin-glycoprotein complex. Badorff C; Lee GH; Knowlton KU Herz; 2000 May; 25(3):227-32. PubMed ID: 10904843 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of RNA Helicase Activity Prevents Coxsackievirus B3-Induced Myocarditis in Human iPS Cardiomyocytes. Yun SH; Shin HH; Ju ES; Lee YJ; Lim BK; Jeon ES Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344926 [TBL] [Abstract][Full Text] [Related]
12. Enterovirus Persistence in Cardiac Cells of Patients With Idiopathic Dilated Cardiomyopathy Is Linked to 5' Terminal Genomic RNA-Deleted Viral Populations With Viral-Encoded Proteinase Activities. Bouin A; Gretteau PA; Wehbe M; Renois F; N'Guyen Y; Lévêque N; Vu MN; Tracy S; Chapman NM; Bruneval P; Fornes P; Semler BL; Andreoletti L Circulation; 2019 May; 139(20):2326-2338. PubMed ID: 30755025 [TBL] [Abstract][Full Text] [Related]
13. Nitric oxide and viral cardiomyopathy. Finkel MS Circulation; 2000 Oct; 102(18):2162-4. PubMed ID: 11056085 [No Abstract] [Full Text] [Related]
14. Baicalein suppresses Coxsackievirus B3 replication by inhibiting caspase-1 and viral protease 2A. Dong Y; Shao E; Li S; Wang R; Wang D; Wang L; Yang H; He Y; Luan T; Chen Y; Wang Y; Lin L; Wang Y; Zhong Z; Zhao W Virol Sin; 2024 Aug; 39(4):685-693. PubMed ID: 39025463 [TBL] [Abstract][Full Text] [Related]
15. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Xiong D; Lee GH; Badorff C; Dorner A; Lee S; Wolf P; Knowlton KU Nat Med; 2002 Aug; 8(8):872-7. PubMed ID: 12118246 [TBL] [Abstract][Full Text] [Related]
16. Involvement of Endoplasmic Reticulum Stress-Mediated C/EBP Homologous Protein Activation in Coxsackievirus B3-Induced Acute Viral Myocarditis. Cai Z; Shen L; Ma H; Yang J; Yang D; Chen H; Wei J; Lu Q; Wang DW; Xiang M; Wang J Circ Heart Fail; 2015 Jul; 8(4):809-18. PubMed ID: 25985795 [TBL] [Abstract][Full Text] [Related]
17. Coxsackievirus B3 infection induced viral myocarditis by regulating the expression pattern of chemokines in cardiac myocytes. Shen Y; Kan QC; Xu W; Chu YW; Xiong SD Iran J Allergy Asthma Immunol; 2009 Mar; 8(1):1-9. PubMed ID: 19279353 [TBL] [Abstract][Full Text] [Related]
18. FTY720 alleviates coxsackievirus B3-induced myocarditis and inhibits viral replication through regulating sphingosine 1-phosphate receptors and AKT/caspase-3 pathways. Wang X; Li M; Yu Y; Liu G; Yu Y; Zou Y; Ge J; Chen R J Cell Physiol; 2019 Aug; 234(10):18029-18040. PubMed ID: 30843214 [TBL] [Abstract][Full Text] [Related]
19. Biphasic and cardiomyocyte-specific IFIT activity protects cardiomyocytes from enteroviral infection. Kimura T; Flynn CT; Alirezaei M; Sen GC; Whitton JL PLoS Pathog; 2019 Apr; 15(4):e1007674. PubMed ID: 30958867 [TBL] [Abstract][Full Text] [Related]
20. Cleavage and Sub-Cellular Redistribution of Nuclear Pore Protein 98 by Coxsackievirus B3 Protease 2A Impairs Cardioprotection. Hanson PJ; Hossain AR; Qiu Y; Zhang HM; Zhao G; Li C; Lin V; Sulaimon S; Vlok M; Fung G; Chen VH; Jan E; McManus BM; Granville DJ; Yang D Front Cell Infect Microbiol; 2019; 9():265. PubMed ID: 31396490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]